Speaker Profile
Ph.D., Professor, Hebrew U.
Biography
Professor Tabach leads the Deep Genomics Laboratory at the Hebrew University Medical School and is the founder of three companies specializing in genomics, cancer, and genetic diseases. He earned his PhD from the Weizmann Institute in systems biology and cancer, followed by postdoctoral training at Harvard Medical School in Professor Ruvkun’s lab, where he uncovered small-RNAi pathways and mechanisms underlying genetic diseases by developing multi-omics methodologies.
His research identifies novel drug targets that reveal cancer vulnerabilities by deciphering the exceptional responder phenomenon- rare stage-IV patients who experience remarkable tumor regression - enabling the selective elimination of cancer cells while minimizing harm to healthy tissue.
Through both academic work and entrepreneurial initiatives, Professor Tabach develops innovative solutions for cancer, aging, and genetic diseases by translating animal “super-traits” into RNA-based therapies for humans. His functional genomics discoveries have revealed key disease pathways and cancer genes, significantly advancing drug discoveries and personalized treatment.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Mark Daly, Broad Institute (implied from context, but you didn’t restate – leaving just content here as requested)
PMWC Award Ceremony
• Mark Daly, Broad Institute
• Gordon Sanghera, Oxford Nanopore
The Data Factory: Building Systems to Integrate Millions of Genomes for Variant Interpretation
• Chair: Stephen B. Montgomery, Stanford
• Carlos D. Bustamante, University of Oklahoma
• Mark Daly, Broad Institute/FinnGen
• Manuel Rivas, Stanford
• Mark McCarthy, Genentech
• Nilah Ioannidis, UC Berkeley/UCSC
Beyond the Read: Integrating Long-Read Data into the Clinical Variant Pipeline
• Chair: Gordon Sanghera, Oxford Nanopore Technologies
• Hanlee P. Ji, Stanford
• Barrett Bready, Nabsys
Keynote: Biobanks and the Road Ahead in Human Genetics
• Mark Daly, Broad Institute/FinnGen
AI and Evolution for Predicting Human Disease Genes
• Chair: Yuval Tabach, Hebrew University
• Nilah Ioannidis, UC Berkeley/UCSC
• Sasa Jenko, European Commission
DNA to Drug, Label & Coverage: From Genetic Signals to Approval & Access
• Chair: Razelle Kurzrock, Medical College of Wisconsin
• Russ B Altman, Stanford
• Slavé Petrovski, AstraZeneca
• Wei Zhou, Broad Institute
25+ Years of the Human Genome — From Bench to Bedside to Beyond
• Chair: Ralph Snyderman, Duke
• J. Craig Venter, Craig Venter Institute (JCVI)
• Brook Byers, KPCB
• Lee Hood, Phenome Health
